AGC Biologics' Ahmed Yahia makes the case for bringing a CDMO in early, ideally before IND-enabling studies, while process and analytics decisions are still flexible. He shares how honest conversations about risk and funding keep timelines grounded, where customization earns its place over standardized platforms, and why sponsor and CDMO teams do their best work when they act as one.
Download Now